Article Text

Download PDFPDF
Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al
  1. Markus Bredemeier
  1. Correspondence to Dr Markus Bredemeier, Rheumatology Service, Hospital Nossa Senhora da Conceição—Grupo Hospitalar Conceição, Av. Francisco Trein 596, sala 2048, Bloco H, Porto Alegre 91350-200, Brazil; markbred{at}

Statistics from

I read with interest the paper by Vital et al,1 a pilot study testing the efficacy of an extra dose of rituximab (completing 3×1000 mg over 4 weeks) in comparison with the standard-dose regimen (2×1000 mg) in rheumatoid arthritis patients with incomplete depletion of B cells after a first 1000 mg dose of rituximab (RTX). The study represents an advance in the knowledge about the effects of RTX, but I have some concerns about the interpretation …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Electronic pages
    Edward M Vital Shouvik Dass Maya H Buch Andrew C Rawstron Paul Emery